Oprelvekin Disease Interactions
There are 4 disease interactions with oprelvekin.
Oprelvekin (applies to oprelvekin) fluid retention
Major Potential Hazard, High plausibility. Applicable conditions: Hypokalemia, Congestive Heart Failure
Oprelvekin causes fluid retention that can result in peripheral edema, dyspnea on exertion, pulmonary edema, atrial arrhythmias, dilution decreases in hemoglobin and hematocrit and changes in serum electrolyte concentrations. Therapy with oprelvekin should be administered cautiously in patients adversely affected by fluid retention, such as patients with congestive heart failure. Clinical monitoring of fluid status and electrolyte levels is recommended.
References
- (2001) "Product Information. Neumega (oprelvekin)." Genetics Institute
Oprelvekin (applies to oprelvekin) arrhythmias
Moderate Potential Hazard, High plausibility.
Transient artrial arrhythmias (fibrillation and flutter) have occurred in approximately 10% of patients receiving oprelvekin. Cardiac conditions, previous cardiotoxic chemotherapy, or advanced age are considered risk factors for development of oprelvekin- associated arrhythmias. Therapy with oprelvekin should be administered cautiously in patients with or predisposed to artrial arrhythmias.
References
- (2001) "Product Information. Neumega (oprelvekin)." Genetics Institute
Oprelvekin (applies to oprelvekin) papilledema
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Brain/Intracranial Tumor
Papilledema has been reported in 2% of patients receiving oprelvekin. Therapy with oprelvekin should be administered cautiously in patients with papilledema or CNS tumors as papilledema can be worsened or induced during therapy.
References
- (2001) "Product Information. Neumega (oprelvekin)." Genetics Institute
Oprelvekin (applies to oprelvekin) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Oprelvekin is primarily eliminated by the kidneys and drug exposure was significantly increased in patients with severe renal impairment (CrCl <30 mL/min). The recommended dose in these patients is 50 mcg/kg once a day. No significant changes were observed in patients with mild or moderate impairment. Fluid retention associated with oprelvekin has not been studied in patients with renal impairment, but fluid balance should be carefully monitored in these patients.
References
- (2001) "Product Information. Neumega (oprelvekin)." Genetics Institute
Oprelvekin drug interactions
There are 8 drug interactions with oprelvekin.
More about oprelvekin
- oprelvekin consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: interleukins
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.